Showing 8 posts of 8 posts found.


AstraZeneca’s Calquence fails to improve survival rates in coronavirus patients

November 12, 2020
Business Services AZ, AstraZeneca, Calquence

AstraZeneca’s Calquence has failed to improve survival rates and prevent lung failure in patients hospitalised with COVID-19.  Calquence (acalabrutinib) is …


Two CHMP recommendations for AstraZeneca: Imfinzi in first-line lung cancer, Calquence in chronic lymphocytic leukaemia

July 27, 2020
Sales and Marketing AstraZeneca, CHMP, Calquence, EMA, Imfinzi

AstraZeneca has secured two new recommendations for approval of its products from the European Medicines Agency’s Committee for Medicinal Products …


AstraZeneca’s BTK inhibitor Calquence shows promise in aiding recovery of severe COVID-19 patients

June 8, 2020
Research and Development, Sales and Marketing AstraZeneca, COVID-19, Calquence, coronavirus, pharma

AstraZeneca has revealed more data in its efforts to find an effective therapy for those affected by the novel coronavirus.


AstraZeneca to pit blood cancer drug Calquence against COVID-19 with the company’s fastest-ever trial launch

April 14, 2020
Manufacturing and Production, Research and Development AstraZeneca, COVID-19, Calquence, coronavirus, pharma

As the R&D race against COVID-19 continues, AstraZeneca is poised to launch a global, multicentre clinical trial to test its …

AstraZeneca’s trial of leukaemia drug Calquence yields positive results

December 9, 2019
Sales and Marketing AstraZeneca, Calquence, leukaemia, phase 3

AstraZeneca confirmed it had recorded positive results from its Phase 3 trial of Calquence plus obinutuzumab in leukaemia. The trial …

FDA approves AstraZeneca’s Calquence in chronic lymphoma

November 25, 2019
Sales and Marketing Astrazenaca, Calquence, FDA, Health Canada, leukaemia, oncology

The FDA has approved AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic …


AstraZeneca’s Calquence shows strength in most common adult leukaemia

June 6, 2019
Research and Development AstraZeneca, Calquence, chronic lymphocytic leukaemia, pharma

AstraZeneca has unveiled new Phase 3 data for Calquence (acalabrutinib) in treatment-naïve chronic lymphocytic leukaemia, showing that the drug met …


AZ ends Calquence trial early after Phase 3 success in chronic lymphocytic leukaemia

May 8, 2019
Research and Development AstraZeneca, Calquence, pharma

AstraZeneca has unveiled new Phase 3 data on the efficacy of its Bruton tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in …

Latest content